Literature DB >> 32304240

The carbon footprint of pathology testing.

Scott McAlister1, Alexandra L Barratt2, Katy Jl Bell2, Forbes McGain1,3.   

Abstract

OBJECTIVES: To estimate the carbon footprint of five common hospital pathology tests: full blood examination; urea and electrolyte levels; coagulation profile; C-reactive protein concentration; and arterial blood gases. DESIGN,
SETTING: Prospective life cycle assessment of five pathology tests in two university-affiliated health services in Melbourne. We included all consumables and associated waste for venepuncture and laboratory analyses, and electricity and water use for laboratory analyses. MAIN OUTCOME MEASURE: Greenhouse gas footprint, measured in carbon dioxide equivalent (CO2 e) emissions.
RESULTS: CO2 e emissions for haematology tests were 82 g/test (95% CI, 73-91 g/test) for coagulation profile and 116 g/test (95% CI, 101-135 g/test) for full blood examination. CO2 e emissions for biochemical tests were 0.5 g/test CO2 e (95% CI, 0.4-0.6 g/test) for C-reactive protein (low because typically ordered with urea and electrolyte assessment), 49 g/test (95% CI, 45-53 g/test) for arterial blood gas assessment, and 99 g/test (95% CI, 84-113 g/test) for urea and electrolyte assessment. Most CO2 e emissions were associated with sample collection (range, 60% for full blood examination to 95% for coagulation profile); emissions attributable to laboratory reagents and power use were much smaller.
CONCLUSION: The carbon footprint of common pathology tests was dominated by those of sample collection and phlebotomy. Although the carbon footprints were small, millions of tests are performed each year in Australia, and reducing unnecessary testing will be the most effective approach to reducing the carbon footprint of pathology. Together with the detrimental health and economic effects of unnecessary testing, our environmental findings should further motivate clinicians to test wisely.
© 2020 AMPCo Pty Ltd.

Entities:  

Keywords:  Climate change; Environmental policy

Mesh:

Year:  2020        PMID: 32304240     DOI: 10.5694/mja2.50583

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.

Authors:  Jake T W Williams; Katy J L Bell; Rachael L Morton; Mbathio Dieng
Journal:  Appl Health Econ Health Policy       Date:  2022-10-05       Impact factor: 3.686

2.  The carbon footprint of hospital diagnostic imaging in Australia.

Authors:  Scott McAlister; Forbes McGain; Matilde Petersen; David Story; Kate Charlesworth; Glenn Ison; Alexandra Barratt
Journal:  Lancet Reg Health West Pac       Date:  2022-05-03

3.  Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.

Authors:  Deonna M Ackermann; Amelia K Smit; Monika Janda; Cathelijne H van Kemenade; Mbathio Dieng; Rachael L Morton; Robin M Turner; Anne E Cust; Les Irwig; Jolyn K Hersch; Pascale Guitera; H Peter Soyer; Victoria Mar; Robyn P M Saw; Donald Low; Cynthia Low; Dorothy Drabarek; David Espinoza; Jon Emery; Peter Murchie; John F Thompson; Richard A Scolyer; Anthony Azzi; Alister Lilleyman; Katy J L Bell
Journal:  Trials       Date:  2021-05-04       Impact factor: 2.279

Review 4.  Health, financial and environmental impacts of unnecessary vitamin D testing: a triple bottom line assessment adapted for healthcare.

Authors:  Matilde Breth-Petersen; Katy Bell; Kristen Pickles; Forbes McGain; Scott McAlister; Alexandra Barratt
Journal:  BMJ Open       Date:  2022-08-23       Impact factor: 3.006

Review 5.  Environmental sustainability in anaesthesia and critical care.

Authors:  Forbes McGain; Jane Muret; Cathy Lawson; Jodi D Sherman
Journal:  Br J Anaesth       Date:  2020-08-12       Impact factor: 9.166

6.  High value health care is low carbon health care.

Authors:  Alexandra L Barratt; Katy Jl Bell; Kate Charlesworth; Forbes McGain
Journal:  Med J Aust       Date:  2021-11-14       Impact factor: 12.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.